Seroconversion rate evolution of patients with blood samples obtained with a median of 6 months from the end of BsAbs treatment. Posttreatment setting 2 corresponds to late posttreatment (>6 months after treatment with BsAbs), the figure also shows the moment of COVID vaccination, time of administration of BsAbs treatment, titers of seroconversion based on measurement of anti-S protein levels, and the moment of SARS-CoV-2 infection (A-G).